Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
Dick de Zeeuw(University Medical Center Groningen), Glenn M. Chertow(Stanford Health Care), Janet Wittes(Deloitte (United States)), Giuseppe Remuzzi(Mario Negri Institute for Pharmacological Research), John J.V. McMurray(University of Glasgow), Angie Goldsberry(Reata Pharmaceuticals (United States)), Hiddo J.L. Heerspink(University Medical Center Groningen), Christoph Wanner(Universitätsklinikum Würzburg), Melanie Chin(Reata Pharmaceuticals (United States)), Nosratola D. Vaziri(University of California, Irvine), Paul Audhya(Reata Pharmaceuticals (United States)), Tadao Akizawa(Showa University), Danielle Wrolstad(Statistics Collaborative), Melissa Krauth(Reata Pharmaceuticals (United States)), Mark T. Houser(AstraZeneca (United States)), Heidi Christ‐Schmidt(Statistics Collaborative), Colin J. Meyer(Reata Pharmaceuticals (United States)), Robert D. Toto(Southwestern Medical Center), Hans‐Henrik Parving(University of Copenhagen), George L. Bakris(Pennsylvania State System of Higher Education)
Cited by 990
Related Papers
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
|Hypertension|2003|13.3k
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization
|New England Journal of Medicine|2004|11.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k